Researchers say they have identified genetic variants that can increase PSA concentrations and prostate cancer risk.
A new study suggests that PSA measurements taken over time may improve the accuracy of detecting aggressive prostate cancer.
It is hoped that selective screening, selective biopsy, and selective therapy will further decrease the morbidity associated with screening.
Shared decision-making about screening recommended for men aged 55-69 years.
Median survival time from diagnosis improved by a median of 43 months from the pre-PSA to the post-PSA era.
Pathologic progression not more likely in patients who start active surveillance with a PSA of 10 ng/mL or higher, study finds.
Study reveals no significant association between BMI and prebiopsy PSA, Gleason score, clinical T stage, and D'Amico risk.
Most men with biopsy-detected cancer undergo treatment, regardless of age, comorbidities.
PSA at age 40 to 55 correlates with risk of death or metastasis during 25 to 30 years of follow-up.
New findings provide a rationale for immunotherapy as an early step in sequencing treatment algorithm for mCRPC.
American College of Physicians' new screening guidance committee urges caution
New findings raise questions about PSA screening criteria.
Stopping PSA testing at age 70 may be premature, at least in men with high-risk disease and long life expectancies, researchers conclude.
The survival benefit is limited to men aged 55-69 years at initial screening, large European study finds.
Use of biennial strategy with longer interval for low PSA levels reduces tests, false-positive results
Much of variation in use of informed decision-making due to physicians' attitudes to screening.
PSA concentrations are higher in men who engage in more sedentary behavior and lower levels of light physical activity, a study found.
Researchers urge prostate biopsies for men with a low neutrophil count and increased serum PSA level.